Denver, Colorado – The market is feeling the effect of Joe Rogan getting in President Trump’s ear and psychedelic therapeutics gaining regulatory tailwinds.
Meanwhile, adjacent sectors are quietly building foundational breakthroughs. Wearables are evolving into neural interfaces, biomaterials are transitioning from lab curiosity to production reality, and oncology platforms continue their grind through clinical validation.
Kraig Biocraft Laboratories- From Lab to Loom
Kraig Biocraft Laboratories (OTCQB:KBLB) is no longer just talking about spider silk, it’s producing it at scale. The company’s announcement that it is processing nearly 1.8 metric tons of recombinant spider silk cocoons marks a meaningful operational milestone. This follows a record-setting March production run and an additional half-ton now accounted for, signaling that its multi-year infrastructure buildout is beginning to translate into tangible output.
What matters here is not just volume, but validation. Kraig is entering the reeling phase, converting cocoons into usable silk, a critical step toward commercialization. If completed as expected, this would represent the largest known stockpile of recombinant spider silk in history, positioning the company to finally test real-world demand across luxury textiles, performance materials, and industrial applications.
The broader implication is that biomaterials may be approaching an inflection point similar to early synthetic biology. With leadership physically onsite in Asia overseeing scale-up, Kraig is attempting to de-risk the manufacturing side, a hurdle that has historically derailed many advanced material startups. Its recent feature in National Geographic underscores growing mainstream awareness, but the market will ultimately focus on whether supply can meet consistent, revenue-generating demand.
One of the initial target markets for these high-performance fibers is the wearable devices space.
Wearable Devices- Neural Interfaces Go Mainstream?
Wearable Devices (NASDAQ:WLDS) is positioning itself at the intersection of AI, AR, and human-computer interaction. Its partnership with Meta-Bounds aims to integrate its Mudra neural wristband into augmented reality systems, enabling gesture-free, intuitive “spatial interaction.” This is more than incremental UX improvement, it’s a step toward frictionless control in immersive environments.
The near-term roadmap focuses on building a working control layer for AR glasses, with a planned showcase at AWE 2026. Longer term, the companies are targeting enterprise deployments, where hands-free interaction could drive productivity gains in logistics, healthcare, and industrial workflows. With a low float (~2.13M shares), the stock sits squarely in the high-volatility category favored by momentum traders.
The strategic question is whether neural input becomes a standard interface layer or remains niche. If adoption accelerates, WLDS could benefit from early-mover advantage. If not, it risks being outpaced by larger ecosystem players. Either way, this partnership signals that the race to control the human-device interface is heating up.
Artelo Biosciences- A New Path in Pain Management
Artelo (NASDAQ:ARTL) is taking a different approach to one of medicine’s most entrenched challenges: pain treatment. Its FABP5 inhibitor, ART26.12, is gaining credibility following a peer-reviewed publication in the European Journal of Pain, reinforcing its mechanism as a non-opioid alternative.
The data points to efficacy across multiple pain models, neuropathic, inflammatory, and cancer-related, while maintaining a clean safety profile in early human trials. That combination is critical in a landscape still grappling with the fallout from opioid dependency and the limitations of NSAIDs. With zero drug-related adverse events reported in its Phase 1 study, ART26.12 is now advancing toward multiple ascending dose trials.
With a very low float (~644K shares), ARTL sits in a category where scientific validation can quickly translate into outsized price movement. But the real story is structural: if FABP5 inhibition proves viable, it could represent a first-in-class mechanism, opening a new therapeutic category rather than competing within an existing one.
Enveric Biosciences- Fueling the Pipeline
Enveric’s (NASDAQ:ENVB) latest move is less about data and more about durability. The company closed a $5 million upfront private placement, with the potential to raise up to $13.9 million through warrant exercises. In the current biotech environment, capital access is strategy.
As one of the “Rogan’s Runners,” Enveric is developing neuroplastogenic compounds targeting psychiatric conditions. These therapies aim to deliver the benefits of psychedelics without the hallucinogenic experience, a key differentiator if regulators demand broader accessibility.
The financing structure, priced at-the-market with attached warrants, suggests a balance between immediate funding needs and future upside participation. While dilution remains a consideration, the raise provides runway to advance clinical programs at a time when policy momentum around psychedelic research appears to be building.
Theriva Biologics- Oncology Data Builds Quietly
Theriva (NYSE:TOVX) is preparing to present new data from its VIRAGE Phase 2b trial at AACR 2026, focusing on VCN-01 in metastatic pancreatic cancer, a notoriously difficult indication. The updated analysis highlights immune-mediated mechanisms and improved outcomes across subgroups, including patients with liver metastases.
What stands out is regulatory alignment. The company reports it has reached agreement with both the FDA and EMA on a pivotal Phase 3 trial design, which is a critical step toward potential commercialization. That reduces one layer of uncertainty, even as clinical risk remains high.
In a market often distracted by flashier narratives, oncology programs like this can be overlooked. But pancreatic cancer represents a high unmet need, and incremental improvements in survival or response duration can carry significant clinical and commercial value.
Rogan’s Runners- Psychedelics Enter the Policy Fast Lane
Psyence Biomedical- Owning the Supply Chain
Psyence (NASDAQ:PBM) is carving out a unique niche by focusing on GMP-grade ibogaine production and ethical sourcing. As regulatory signals point toward expanded research, the company’s vertically integrated supply chain, spanning African sourcing to pharmaceutical-grade manufacturing, positions it as a potential backbone provider for the sector.
Its claim of holding ready-to-deploy GMP ibogaine inventory is particularly notable in a market where supply constraints have historically slowed research. If regulatory pathways open, access to standardized material could become a competitive moat.
Clearmind Medicine- Safety First in Psychedelic Evolution
Clearmind (NASDAQ:CMND) is advancing a non-hallucinogenic psychedelic-derived treatment for alcohol use disorder, with recent trial data confirming safety and tolerability at higher doses. This “second-generation” approach may prove critical in broadening acceptance beyond controlled clinical environments.
By removing the hallucinogenic component, CMND-100 could sidestep some regulatory and societal barriers, potentially accelerating adoption if efficacy follows.
Compass Pathways- The Frontrunner
Compass (NASDAQ:CMPS) continues to lead the space with late-stage clinical data for COMP360 psilocybin, including two positive Phase 3 trials in treatment-resistant depression. With FDA engagement already underway, it is among the closest to potential commercialization.
The company’s scale, over 1,000 trial participants, sets it apart from peers, reinforcing its position as a bellwether for the entire sector.
Helus Pharma- Leadership Reset Amid Momentum
Helus (NASDAQ:HELP) adds a governance twist to the Rogan’s Runners narrative with a CEO transition, reinstating co-founder Eric So as interim chief. While leadership changes can introduce uncertainty, the company maintains focus on upcoming Phase 3 data for HLP003.
In a sector driven by milestones, execution during leadership transitions becomes critical—especially with late-stage data on the horizon.
Sources: https://www.businesswire.com/news/home/20260417670024/en/
https://www.businesswire.com/news/home/20260418890886/en/
https://www.businesswire.com/news/home/20260418890886/en/
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.
For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
CONTACT:
24/7 Market News
[email protected]